Showing results (21-30 of 24) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The Lancet. HIV|July 22, 2022
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trialAnna Turkova, Hylke Waalewijn, Man K Chan, et al.Contemporary Clinical Trials|April 18, 2024
D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 yearsAnna Turkova, Man K Chan, Cissy Kityo, et al.Ebiomedicine|September 27, 2025
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trialLisanne A H Bevers, Gabriela Toledo, Muzamil Kisekka, et al.Eclinicalmedicine|June 12, 2023
Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV - Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trialAlexandra Compagnucci, Man K Chan, Yacine Saïdi, et al.Pageof 3